Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-08 @ 7:24 PM
Study NCT ID:
NCT02989402
Status:
COMPLETED
Last Update Posted:
2024-05-31
First Post:
2016-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-31
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-08
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-08
First Submit QC Date:
None
Study First Post Date:
2016-12-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-12-08
Results First Submit QC Date:
None
Results First Post Date:
2024-05-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-08
Last Update Post Date:
2024-05-31
Last Update Post Date Type:
ACTUAL